Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Merck
Colorcon
Johnson and Johnson
Healthtrust
McKinsey
Teva
Harvard Business School
Express Scripts

Generated: June 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,268,156

« Back to Dashboard

Which drugs does patent 7,268,156 protect, and when does it expire?

Patent 7,268,156 protects COREG CR and is included in one NDA.

Protection for COREG CR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-seven patent family members in fourteen countries.
Summary for Patent: 7,268,156
Title:Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
Abstract:The present invention relates to carvedilol phosphate salts, which include novel crystalline forms of carvedilol dihydrogen phosphate (i.e., dihydrogen phosphate salt of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol) and/or carvedilol hydrogen phosphate, etc.), and/or solvates thereof, compositions containing the aforementioned salts and/or solvates, and methods of using the aforementioned salts and/or solvates to treat hypertension, congestive heart failure and angina, etc.
Inventor(s): Brook; Christopher S. (King of Prussia, PA), Chen; Wei (Woodbury, MN), Spoors; Paul G. (King of Prussia, PA)
Assignee: SB Pharmco Puerto Rico Inc. (Hato Rey, PR)
Application Number:10/518,654
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,268,156
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 7,268,156

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-001 Oct 20, 2006 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-002 Oct 20, 2006 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-003 Oct 20, 2006 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-004 Oct 20, 2006 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,268,156

PCT Information
PCT FiledJune 27, 2003PCT Application Number:PCT/US03/20408
PCT Publication Date:January 08, 2004PCT Publication Number: WO20/04/002419

Non-Orange Book US Patents Family Members for Patent 7,268,156

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,902,378 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment ➤ Sign Up
7,626,041 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment ➤ Sign Up
7,893,100 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment ➤ Sign Up
7,759,384 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Fish and Richardson
Federal Trade Commission
Covington
Deloitte
Express Scripts
Fuji
Cantor Fitzgerald
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.